Research progress in clinical research of adjuvant targeted therapy with EGFR-TKI for postoperative non-small cell lung cancer
GU Weiguo
YU Feng
NIE Shanlin
LI Cong
QIU Feng
Abstract：Nowadays, lung cancer is currently the most malignant tumor to human life worldwide.Non-small cell lung cancer (NSCLC) accounts for more than 85％of lung cancer, and about 20％-25％of NSCLC patients can receive radical surgery.Cisplatin based adjuvant chemotherapy is the standard treatment for complete resection of stageⅡ-Ⅲa NSCLC, but its efficiency is low and adverse reactions are often intolerable.Targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is effective for advanced NSCLC patients with EGFR mutation.Recently, the results of adjuvant EGFR-TKIs therapy with positive EGFR mutation after early and mid-term NSCLC surgery have been published continuously.The adjuvant EGFR-TKIs treatment after lung cancer surgery can improve the efficacy and quality of life, but there is still some controversy.This article reviews the efficacy and safety of EGFR-TKIs targeted drug therapy in early and mid-term NSCLC surgery at home and abroad in recent years.
Keywords：Non-small cell lung cancerPostoperative adjuvantEpidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)Clinical study
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1131-1134 )